ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Folate receptor alpha in platinum-resistant ovarian cancer: prevalence in a multicenter Polish cohort and review of the evidence.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Context-dependent roles of HtrA2/Omi in ovarian cancer: mitochondrial apoptotic function linking platinum sensitivity and acquired chemoresistance-a narrative review.Translational cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFolate receptor alpha (FRα, FOLR1) is the required biomarker for mirvetuximab soravtansine, a treatment option for patients with platinum-resistant ovarian cancer. Since its approval, the drug has been introduced into national drug programs, but prevalence data from the Polish population are lacking. This study provides the first multicenter assessment of FOLR1 expression in Polish ovarian cancer in the context of treatment eligibility.
methodsWe retrospectively analyzed two institutional cohorts comprising 229 epithelial ovarian cancer cases from the Oncology Center in Bydgoszcz and the National Institute of Oncology in Warsaw. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue using the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay on the BenchMark ULTRA platform. Membranous staining of moderate or strong intensity in ≥ 75% of viable tumor cells was considered positive, in accordance with criteria for FOLR1-targeted therapy.
resultsPositive FOLR1 expression was observed in 116 of 229 (50.7%, 95% CI 44.2-57.2) analyzed tumors, with 40% showing high expression. In most of these cases, staining intensity was moderate to strong, meeting the established threshold for therapeutic eligibility. In ~ 18% of tumors, FOLR1 expression fell into the borderline range (65-85%).
conclusionApproximately half of the ovarian cancer patients in this multicenter Polish cohort demonstrated FOLR1 positivity. Although this prevalence is lower than that reported in high-grade serous carcinoma cohorts, it likely reflects histological heterogeneity and methodological differences between studies. These findings provide the first population-based evidence from Poland and support the implementation of FOLR1 testing to guide access to mirvetuximab soravtansine. Further research integrating clinical and molecular data is warranted to validate these results and assess implications for cost-effectiveness and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.